These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Using stable isotope labeling to advance our understanding of Alzheimer's disease etiology and pathology. Hark TJ; Savas JN J Neurochem; 2021 Oct; 159(2):318-329. PubMed ID: 33434345 [TBL] [Abstract][Full Text] [Related]
4. Amyloid-β as a biomarker for Alzheimer's disease: quantification methods in body fluids. Galozzi S; Marcus K; Barkovits K Expert Rev Proteomics; 2015 Aug; 12(4):343-54. PubMed ID: 26153725 [TBL] [Abstract][Full Text] [Related]
5. The use of mass spectrometry to study amyloid-β peptides. Grasso G Mass Spectrom Rev; 2011; 30(3):347-65. PubMed ID: 21500241 [TBL] [Abstract][Full Text] [Related]
6. Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applications. Bros P; Delatour V; Vialaret J; Lalere B; Barthelemy N; Gabelle A; Lehmann S; Hirtz C Clin Chem Lab Med; 2015 Sep; 53(10):1483-93. PubMed ID: 25719328 [TBL] [Abstract][Full Text] [Related]
7. Mass spectrometry is a multifaceted weapon to be used in the battle against Alzheimer's disease: Amyloid beta peptides and beyond. Grasso G Mass Spectrom Rev; 2019 Jan; 38(1):34-48. PubMed ID: 29905953 [TBL] [Abstract][Full Text] [Related]
8. Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease. Robinson RA; Amin B; Guest PC Adv Exp Med Biol; 2017; 974():21-48. PubMed ID: 28353223 [TBL] [Abstract][Full Text] [Related]
9. Potential therapeutic agents against Alzheimer's disease from natural sources. Park SY Arch Pharm Res; 2010 Oct; 33(10):1589-609. PubMed ID: 21052936 [TBL] [Abstract][Full Text] [Related]
10. Next-generation proteomics technologies in Alzheimer's disease: from clinical research to routine diagnostics. Weiner S; Blennow K; Zetterberg H; Gobom J Expert Rev Proteomics; 2023; 20(7-9):143-150. PubMed ID: 37701966 [TBL] [Abstract][Full Text] [Related]
11. Current thinking on the mechanistic basis of Alzheimer's and implications for drug development. Ising C; Stanley M; Holtzman DM Clin Pharmacol Ther; 2015 Nov; 98(5):469-71. PubMed ID: 26250900 [TBL] [Abstract][Full Text] [Related]
12. Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases. Cilento EM; Jin L; Stewart T; Shi M; Sheng L; Zhang J J Neurochem; 2019 Nov; 151(4):397-416. PubMed ID: 30474862 [TBL] [Abstract][Full Text] [Related]
13. Alzheimer's disease 2012: the great amyloid gamble. Marchesi VT Am J Pathol; 2012 May; 180(5):1762-7. PubMed ID: 22472273 [TBL] [Abstract][Full Text] [Related]